AGENUS INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
AGENUS INC (AGEN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $27.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-16
- AGENUS INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $27.00K, a 57.81% decline from fiscal 2024.
- AGENUS INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $64.00K, a 392.31% increase from fiscal 2023.
- AGENUS INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $13.00K, a 81.43% decline from fiscal 2022.
- AGENUS INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $70.00K, a 98.33% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2025-12-31 | $27.00K 10-K · filed 2026-03-16 |
| 2024-12-31 | $64.00K 10-K · filed 2026-03-16 |
| 2023-12-31 | $13.00K 10-K · filed 2026-03-16 |
| 2022-12-31 | $70.00K 10-K · filed 2025-03-17 |
| 2021-12-31 | $4.20M 10-K · filed 2024-03-14 |
| 2020-12-31 | $1.20M 10-K · filed 2023-03-16 |
| 2019-12-31 | $385.00K 10-K · filed 2022-03-01 |
| 2018-12-31 | $399.00K 10-K · filed 2021-03-16 |
| 2017-12-31 | $132.00K 10-K · filed 2020-03-16 |
| 2016-12-31 | $445.00K 10-K · filed 2019-03-18 |
| 2015-12-31 | $1.20M 10-K · filed 2018-03-16 |
| 2014-12-31 | $45.00K 10-K · filed 2017-03-16 |
| 2013-12-31 | $5.00K 10-K · filed 2016-03-15 |
| 2012-12-31 | $12.00K 10-K · filed 2015-03-16 |
| 2011-12-31 | $0.00 10-K · filed 2014-03-07 |
| 2010-12-31 | $0.00 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |